926. Risk factors for post-letermovir cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplant (HSCT) recipients

BACKGROUND: Letermovir (LTMV) is approved for CMV prophylaxis during the first 100 days after HSCT. Thereafter, CMV reactivation (CMVr) may still occur. This study aims to evaluate the incidence and risk factors for any CMVr and clinically significant CMV infection (csCMVi) in patients who received...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendoza, Maria Alejandra, Thoendel, Matthew J, Razonable, Raymund R, Alkhateeb, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677946/
http://dx.doi.org/10.1093/ofid/ofad500.971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677946/
http://dx.doi.org/10.1093/ofid/ofad500.971

Ejemplares similares